Chronic Kidney Disease After 40: Reading eGFR, Albuminuria, and Risk Without Self-Treating

After age forty, chronic kidney disease should not be reduced to a single kidney number, especially if you have diabetes, hypertension, or a test result your doctor wants to follow. This evidence bundle points to eGFR, cystatin C, UACR, and cardiovascular risk as pieces that need to be read together.

This article is not telling you to start, stop, or change medication yourself. It is meant to help you have a clearer conversation with your doctor: which values matter, what kind of risk they signal, where the evidence is strong, and where the Thai context still requires caution.

Three-Line Summary

1. When cystatin C-based eGFR is meaningfully worse than creatinine-based eGFR, a meta-analysis found higher associated risks of death, cardiovascular events, and progression to kidney failure.
2. Elevated UACR in people with diabetes or hypertension is a strong predictor of faster eGFR decline and adverse cardiovascular outcomes.
3. Some medication classes, including SGLT2 inhibitors and RAS inhibitors, have evidence for slowing kidney disease progression in specific contexts, but medication decisions must be made with a doctor, not from an article.

Chronic Kidney Disease Is About Risk, Not One Number

The KDIGO 2024 guideline is a clinical practice guideline for evaluating and managing chronic kidney disease. Across this evidence bundle, the practical picture is that chronic kidney disease should be read as a risk profile rather than as one isolated value.

The repeated measures in the research are eGFR, which estimates kidney filtration; cystatin C, which can be used to calculate eGFR in another way; and UACR, which reflects urinary albumin relative to creatinine.

For adults 40+, the key point is this: if you have diabetes, hypertension, or kidney results your doctor wants to monitor, do not only ask whether the kidney value is still “passing.” Ask what the full profile says about long-term kidney and cardiovascular risk.

Creatinine and Cystatin C May Tell Different Stories

A 2025 JAMA meta-analysis found that meaningful discordance between creatinine-based eGFR and cystatin C-based eGFR, especially when cystatin C indicates worse kidney function, is associated with higher risks of all-cause mortality, cardiovascular events, and progression to kidney failure.

This does not mean everyone should independently order cystatin C testing right away. It means that when a physician uses more than one way to assess kidney function, a result that does not line up may carry risk information and should not be dismissed as just lab noise.

⚠️ Caveat: this was a meta-analysis reporting associations with clinical outcomes. It is not an instruction for universal extra testing, and it does not make any single test result a basis for self-directed treatment.

UACR: Albumin in Urine That People With Diabetes or Hypertension Should Know

An individual-participant data meta-analysis in people with diabetes or hypertension found that elevated UACR is a strong predictor of faster eGFR decline and adverse cardiovascular outcomes.

This matters because chronic kidney disease does not end with the kidneys. Cardiovascular risk is part of the same picture. If you have diabetes or hypertension, talking with your doctor about UACR is about more than urine. It reads long-term risk for both kidney and heart outcomes.

The evidence bundle does not provide UACR cutoffs for self-interpretation in this article. Use the test result with a clinician who understands your health context and current medications.

Medications With Evidence: Important, But Not a Reason to Start on Your Own

A 2026 JAMA meta-analysis reported that SGLT2 inhibitors significantly reduce the risk of chronic kidney disease progression, including a 50% or greater decline in eGFR and the onset of kidney failure. The finding was seen across a broad range of baseline kidney function and albuminuria levels, regardless of diabetes status.

Another systematic review and individual participant-level meta-analysis in Annals of Internal Medicine in 2024 found that, in people with advanced CKD and eGFR 15-29 mL/min/1.73 m², initiating RAS inhibitors was associated with a lower risk of progressing to kidney failure requiring replacement therapy compared with other antihypertensive strategies.

This is strong evidence that some medication classes have a real role. It is not a reason to buy, start, increase, stop, or switch medication on your own. Chronic kidney disease decisions depend on kidney values, existing medication, blood pressure, diabetes, albuminuria, and other risks that need to be reviewed by a doctor together.

Thai Context: CKDu in Northeast Thailand and Environmental Exposures

A 2025 Journal of Nephrology study in rural Northeast Thailand discussed chronic kidney disease of unknown etiology, or CKDu, and reported that CKDu prevalence was associated with environmental exposures such as groundwater contaminated with heavy metals and pesticides.

Read this carefully: the evidence bundle states that direct causal mechanisms remain uncertain, because the mechanistic data are limited.

⚠️ Caveat: “associated with” is not the same as “proven to cause.” This article should not be used to conclude the risk of any specific area without actual local measurement data.

Reading the Evidence Without Overclaiming

Topic	What the evidence bundle says	Confidence for you
CKD guideline	KDIGO 2024 is a guideline for CKD evaluation and management	Strong within guideline context
Creatinine and cystatin C	When cystatin C indicates worse eGFR, this is associated with higher death, cardiovascular event, and kidney failure risks	Strong for risk prediction
UACR in diabetes or hypertension	Elevated UACR predicts faster eGFR decline and adverse cardiovascular outcomes	Strong
SGLT2 inhibitors	Reduce CKD progression, including eGFR decline of 50% or greater and kidney failure, across risk levels	Strong, but doctor-directed
RAS inhibitors in advanced CKD	Initiation at eGFR 15-29 is associated with lower risk of kidney failure requiring replacement therapy	Strong, but context-specific
CKDu in Northeast Thailand	Associated with groundwater contamination by heavy metals and pesticides, but causal mechanisms remain uncertain	Limited for cause-and-effect conclusions

The overall evidence strength for this topic is strong because it includes a clinical practice guideline, meta-analyses, an individual participant-level meta-analysis, and Thai-context research. The safe conclusion is still cautious: read risk comprehensively and consult a doctor, rather than making decisions from one lab value or one medication name.

When to Talk With a Doctor

Talk with a doctor or qualified professional if you have diabetes, hypertension, eGFR or UACR results that your doctor wants to follow, or test results that seem to tell different stories, such as creatinine-based eGFR and cystatin C-based eGFR pointing in different directions.

If you already take blood pressure medication, diabetes medication, kidney-related medication, or have been advised about SGLT2 inhibitors or RAS inhibitors, do not adjust, add, stop, or start medication on your own. Ask your doctor to interpret the decision together with kidney values, albuminuria, other conditions, and your full medication list.

The goal is not to make everyone afraid of kidney disease. It is to make kidney conversations earlier and more precise. Chronic kidney disease now has clearer evidence for risk assessment and slowing progression, but that evidence must be applied in the context of a real patient, not as a formula from a screen.

This article is for understanding, not personal medical advice. Testing, interpretation, and medication decisions should be made with the doctor or qualified professional who cares for you.